Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Whan In Pharm Co.,Ltd. (016580.KS)
KRW9,870.00
+140.00 (+1.44%)
KR KSC Healthcare Drug Manufacturers - Specialty & Generic
Address
Whanin Building, 11 5855
Seoul, KR
Seoul, KR
CEO
Wonbum Lee
Website
whanin.com
IPO
2000-01-04
ISIN KR7016580003
Description
Whan In Pharm Co.,Ltd. is a South Korean pharmaceutical enterprise specializing in the research, development, manufacturing, promotion, and distribution of therapeutic products. Their comprehensive portfolio encompasses treatments for mental health conditions (such as antidepressants and antipsychotics), neurological disorders (including nootropics, anti-dementia, and anti-epileptics), cardiovascular and gastrointestinal ailments, infectious diseases, allergies, pain and inflammation, metabolic imbalances, respiratory issues, and a variety of other central nervous system applications. Established in 1978, the company's corporate headquarters are situated in Seoul, South Korea.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW9,870.00
+140.00 (+1.44%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
55.0K
Beta
0.18
Float Shares
10.87M
Free Float %
71.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.48% | -4.06% | -11.63% | -3.88% | -9.56% | -4.14% | -11.03% | -34.65% | -52.47% | -39.48% | +523.35% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
9,870.00
DCF (Unlevered)
10,058.93
+1.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.81
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
4 / 5
High
P/E Score
2 / 5
Medium
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-1.7% Q1'26: +18.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-44.0% Q1'26: +20.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+1.0% Q1'26: +0.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+5.1% Q1'26: +13.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.3% Q1'26: +7.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+21.8% Q1'26: +21.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.03× ★ Q1'26: 0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
145.40B
est: 145.20B (+0.1%)
|
141.38B
est: 150.30B (-5.9%)
|
147.95B
est: 146.77B (+0.8%)
|
154.66B
est: 156.30B (-1.0%)
|
159.18B
est: 170.30B (-6.5%)
|
171.71B
est: 171.70B (+0.0%)
|
177.78B
est: 178.65B (-0.5%)
|
198.93B
est: 192.40B (+3.4%)
|
230.39B
est: 229.50B (+0.4%)
|
259.60B
est: 260.30B (-0.3%)
|
255.21B
est: 256.30B (-0.4%)
|
279.60B
279.60B – 279.60B
+9.1% YoY
|
305.60B
305.60B – 305.60B
+9.3% YoY
|
333.20B
333.20B – 333.20B
+9.0% YoY
|
| EBITDA |
27.33B
est: 26.07B (+4.8%)
|
23.81B
est: 26.98B (-11.8%)
|
38.84B
est: 26.35B (+47.4%)
|
31.98B
est: 28.06B (+14.0%)
|
32.14B
est: 30.57B (+5.1%)
|
35.18B
est: 30.82B (+14.1%)
|
38.03B
est: 32.07B (+18.6%)
|
34.67B
est: 34.54B (+0.4%)
|
40.48B
est: 41.20B (-1.8%)
|
33.44B
est: 40.97B (-18.4%)
|
24.07B
est: 40.34B (-40.3%)
|
44.01B
44.01B – 44.01B
+9.1% YoY
|
48.10B
48.10B – 48.10B
+9.3% YoY
|
52.45B
52.45B – 52.45B
+9.0% YoY
|
| EBIT |
25.41B
est: 22.26B (+14.2%)
|
21.79B
est: 23.04B (-5.4%)
|
36.47B
est: 22.50B (+62.1%)
|
29.32B
est: 23.96B (+22.4%)
|
28.24B
est: 26.11B (+8.2%)
|
31.11B
est: 26.32B (+18.2%)
|
33.99B
est: 27.39B (+24.1%)
|
30.06B
est: 29.49B (+1.9%)
|
33.82B
est: 35.18B (-3.9%)
|
24.99B
est: 33.13B (-24.6%)
|
13.02B
est: 32.62B (-60.1%)
|
35.58B
35.58B – 35.58B
+9.1% YoY
|
38.89B
38.89B – 38.89B
+9.3% YoY
|
42.40B
42.40B – 42.40B
+9.0% YoY
|
| Net Income |
20.51B
est: 16.81B (+22.0%)
|
16.40B
est: 16.40B (+0.0%)
|
27.17B
est: 20.66B (+31.5%)
|
21.52B
est: 18.92B (+13.8%)
|
18.70B
est: 21.31B (-12.3%)
|
23.39B
est: 23.19B (+0.9%)
|
26.66B
est: 25.24B (+5.6%)
|
23.92B
est: 22.50B (+6.3%)
|
29.77B
est: 21.31B (+39.7%)
|
23.38B
est: 24.40B (-4.2%)
|
13.60B
est: 15.12B (-10.1%)
|
20.65B
20.65B – 20.65B
+36.5% YoY
|
23.44B
23.44B – 23.44B
+13.5% YoY
|
26.73B
26.73B – 26.73B
+14.0% YoY
|
| SGA |
19.55B
est: 23.15B (-15.5%)
|
23.40B
est: 23.96B (-2.4%)
|
24.43B
est: 23.40B (+4.4%)
|
24.37B
est: 24.92B (-2.2%)
|
23.57B
est: 27.15B (-13.2%)
|
25.57B
est: 27.37B (-6.6%)
|
29.08B
est: 28.48B (+2.1%)
|
35.29B
est: 30.67B (+15.1%)
|
36.42B
est: 36.59B (-0.5%)
|
38.71B
est: 40.62B (-4.7%)
|
33.74B
est: 40.00B (-15.7%)
|
43.64B
43.64B – 43.64B
+9.1% YoY
|
47.69B
47.69B – 47.69B
+9.3% YoY
|
52.00B
52.00B – 52.00B
+9.0% YoY
|
| EPS |
1,343.00
est: 1,101.00 (+22.0%)
|
1,074.00
est: 1,074.00 (+0.0%)
|
1,780.00
est: 1,353.00 (+31.6%)
|
1,409.44
est: 1,239.00 (+13.8%)
|
1,224.59
est: 1,396.00 (-12.3%)
|
1,531.91
est: 1,519.00 (+0.8%)
|
1,746.22
est: 1,653.50 (+5.6%)
|
1,566.86
est: 1,473.50 (+6.3%)
|
1,950.00
est: 1,396.00 (+39.7%)
|
1,532.37
est: 1,312.00 (+16.8%)
|
857.00
est: 813.00 (+5.4%)
|
1,110.00
1,110.00 – 1,110.00
+36.5% YoY
|
1,260.00
1,260.00 – 1,260.00
+13.5% YoY
|
1,437.00
1,437.00 – 1,437.00
+14.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-28 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-27 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-26 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-22 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-21 | A- | 4/5 | 1/5 | 3/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-20 | A- | 4/5 | 1/5 | 3/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-19 | A- | 4/5 | 1/5 | 3/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-18 | A- | 4/5 | 1/5 | 3/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 3/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
4.51B
OE per share TTM
202.25
Owner's Yield
2.33%
Maintenance CapEx ratio
59.54%
Maint CapEx / Avg PPE
45.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 5 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex KOSPI 226490.KS | 0.00% | 37.5K | 0.15% |
| 2 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 30.8K | 0.46% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 78.8K | 0.39% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 59.3K | 0.28% |
| 5 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 984.42 | 0.33% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
22.37M
Shares Outstanding
15.27M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kwang-Sik Lee | Founder & Chairman | 936M | male |
| JeongBae Gong | Executive Director & GM of Sales | — | male |
| Wonbum Lee | Chief Executive Officer, President & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 016580.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
